Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
AIDS (London, England)|September 24, 2011
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infectionRichard H Haubrich, Sharon A Riddler, Heather Ribaudo, et al.
The Journal of Infectious Diseases|August 22, 2013
Virologic correlates of anti-CMV IgG levels in HIV-1-infected menSara Gianella, Sheldon R Morris, Erick Tatro, et al.
Antiviral Therapy|November 13, 2004
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patientsJulie M Yasuda, Chris Miller, Judith S Currier, et al.
Pharmacogenetics and Genomics|December 3, 2014
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocolsDavid S Lehmann, Heather J Ribaudo, Eric S Daar, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 28, 2014
Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failureRandall G Fisher, Davey M Smith, Ben Murrell, et al.
HIV Clinical Trials|January 31, 2017
HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimenMaile Y Karris, Sonia Jain, Tyler R C Day, et al.
HIV Clinical Trials|July 28, 2015
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexityKaren T Tashima, Katie R Mollan, Lumine Na, et al.
AIDS (London, England)|October 9, 2002
The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysisRichard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
Plos One|June 25, 2011
Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadArt F Y Poon, Jeannette L Aldous, W Christopher Mathews, et al.
AIDS (London, England)|February 19, 2005
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575Richard H Haubrich, Carol A Kemper, Nicholas S Hellmann, et al.
Pageof 4